Co-Authors
This is a "connection" page, showing publications co-authored by YILING LU and GORDON B MILLS.
Connection Strength
8.399
-
Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31; 511(7511):543-50.
Score: 0.489
-
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
Score: 0.455
-
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene. 2011 Nov 10; 30(45):4567-77.
Score: 0.395
-
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003 Oct 10; 278(41):40057-66.
Score: 0.228
-
Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol. 2003 Jun; 7(2):205-28.
Score: 0.226
-
The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene. 1999 Nov 25; 18(50):7034-45.
Score: 0.177
-
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell. 2019 06 10; 35(6):851-867.e7.
Score: 0.172
-
Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. J Immunol. 1998 Nov 15; 161(10):5404-12.
Score: 0.165
-
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. Cancer Cell. 2018 05 14; 33(5):817-828.e7.
Score: 0.159
-
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell. 2018 03 12; 33(3):401-416.e8.
Score: 0.158
-
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017 05 31; 9(392).
Score: 0.149
-
A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv. 2017 Apr; 3(4):e1600957.
Score: 0.148
-
Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol. 2016 08; 43(4):476-83.
Score: 0.140
-
Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep. 2016 05 17; 15(7):1493-1504.
Score: 0.139
-
Verteporfin inhibits YAP function through up-regulating 14-3-3s sequestering YAP in the cytoplasm. Am J Cancer Res. 2016; 6(1):27-37.
Score: 0.135
-
Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. Nat Commun. 2015 Aug 14; 6:7926.
Score: 0.132
-
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell. 2014 Oct 13; 26(4):479-94.
Score: 0.124
-
Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. 2014 May 29; 33(22):2846-56.
Score: 0.114
-
Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
Score: 0.113
-
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012 Nov; 22(11):2120-9.
Score: 0.108
-
Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer. 2012 Nov 15; 131(10):2456-64.
Score: 0.104
-
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62.
Score: 0.101
-
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011 Jul; 1(2):170-85.
Score: 0.099
-
Quantitative proteomic analysis in breast cancer. Drugs Today (Barc). 2011 Feb; 47(2):169-82.
Score: 0.096
-
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics. 2010 Dec; 6(4):129-51.
Score: 0.095
-
Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One. 2010 Mar 26; 5(3):e9910.
Score: 0.091
-
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009 Jun 02; 15(6):539-50.
Score: 0.086
-
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 2008 Nov 19; 100(22):1630-42.
Score: 0.083
-
Bayesian models based on test statistics for multiple hypothesis testing problems. Bioinformatics. 2008 Apr 01; 24(7):943-9.
Score: 0.078
-
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Adv Exp Med Biol. 2008; 617:23-40.
Score: 0.078
-
Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol. 2008; 622:183-95.
Score: 0.078
-
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res. 2007 Dec 15; 13(24):7421-31.
Score: 0.078
-
A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci U S A. 2006 Oct 10; 103(41):15014-9.
Score: 0.071
-
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005 Dec; 4(12):988-1004.
Score: 0.067
-
Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol. 2005; 403:202-15.
Score: 0.063
-
A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies. Nat Cancer. 2024 Oct; 5(10):1579-1595.
Score: 0.062
-
Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem. 2004 Aug 15; 92(6):1115-40.
Score: 0.062
-
Molecular therapeutics: promise and challenges. Semin Oncol. 2004 Feb; 31(1 Suppl 3):39-53.
Score: 0.059
-
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004 Mar 05; 279(10):9653-61.
Score: 0.059
-
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct; 45(10):1113-20.
Score: 0.058
-
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):93-104.
Score: 0.058
-
Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S88-92; discussion S93-6.
Score: 0.055
-
RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array data. Bioinformatics. 2022 11 15; 38(22):5131-5133.
Score: 0.055
-
BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. Cell Rep. 2022 09 13; 40(11):111304.
Score: 0.054
-
Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol. 2002 Apr; 22(7):2099-110.
Score: 0.052
-
A functional genomic approach to actionable gene fusions for precision oncology. Sci Adv. 2022 02 11; 8(6):eabm2382.
Score: 0.052
-
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res. 2002; 107:259-83.
Score: 0.051
-
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol. 2001 Oct; 28(5 Suppl 16):125-41.
Score: 0.050
-
Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A. 2001 Aug 28; 98(18):10031-3.
Score: 0.050
-
Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem. 2001 Jul 20; 276(29):27455-61.
Score: 0.049
-
Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J. 2000 Dec 01; 352 Pt 2:475-82.
Score: 0.048
-
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J. 2000 Nov 15; 352 Pt 1:135-43.
Score: 0.047
-
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020 12 14; 38(6):829-843.e4.
Score: 0.047
-
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):11960-5.
Score: 0.047
-
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. Cancer Immunol Res. 2020 07; 8(7):952-965.
Score: 0.046
-
Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res. 1999 Dec; 5(12):4308-18.
Score: 0.044
-
SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem. 1999 Sep 24; 274(39):27583-9.
Score: 0.044
-
TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data. Mol Cell Proteomics. 2019 08 09; 18(8 suppl 1):S15-S25.
Score: 0.043
-
Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nat Commun. 2018 09 28; 9(1):3982.
Score: 0.041
-
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018 05 03; 9(1):1777.
Score: 0.040
-
Predicting high-risk endometrioid carcinomas using proteins. Oncotarget. 2018 Apr 13; 9(28):19704-19715.
Score: 0.040
-
Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun. 2018 04 03; 9(1):1317.
Score: 0.040
-
Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK. Biochem J. 1998 Mar 15; 330 ( Pt 3):1123-8.
Score: 0.039
-
Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018 03 12; 33(3):450-462.e10.
Score: 0.039
-
Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Res. 2017 11 01; 77(21):e51-e54.
Score: 0.038
-
Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res. 2017 07; 27(7):1112-1125.
Score: 0.037
-
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. NPJ Syst Biol Appl. 2017; 3:8.
Score: 0.037
-
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 2017 02 13; 31(2):225-239.
Score: 0.037
-
Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. J Hepatol. 2016 08; 65(2):325-33.
Score: 0.035
-
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016 Mar 15; 14(10):2476-89.
Score: 0.034
-
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
Score: 0.033
-
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 2015 Oct 12; 28(4):515-528.
Score: 0.033
-
Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. NPJ Syst Biol Appl. 2015; 1:15001.
Score: 0.033
-
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clin Cancer Res. 2016 Jan 15; 22(2):513-23.
Score: 0.033
-
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
Score: 0.033
-
Spatial normalization of reverse phase protein array data. PLoS One. 2014; 9(12):e97213.
Score: 0.031
-
a-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res. 2015 Jan 01; 75(1):203-15.
Score: 0.031
-
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 2014 Dec 08; 26(6):863-879.
Score: 0.031
-
Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics. 2015 Mar 15; 31(6):912-8.
Score: 0.031
-
Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Res. 2015 Feb; 25(2):257-67.
Score: 0.031
-
A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. Cancer Inform. 2014; 13:109-17.
Score: 0.031
-
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 Oct 15; 5(19):9049-64.
Score: 0.031
-
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell. 2014 Sep 08; 26(3):344-357.
Score: 0.031
-
A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014 May 29; 5:3887.
Score: 0.030
-
Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res. 2014 May 01; 20(9):2300-11.
Score: 0.030
-
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1114-9.
Score: 0.030
-
TCPA: a resource for cancer functional proteomics data. Nat Methods. 2013 Nov; 10(11):1046-7.
Score: 0.029
-
Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest. 2013 Sep; 123(9):3740-50.
Score: 0.029
-
Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene. 2014 Jun 26; 33(26):3463-72.
Score: 0.029
-
Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013 Jul; 58(1):182-91.
Score: 0.028
-
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013 Jul; 3(7):761-9.
Score: 0.028
-
Site-specific activation of AKT protects cells from death induced by glucose deprivation. Oncogene. 2014 Feb 06; 33(6):745-55.
Score: 0.028
-
BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal. 2013 Jan 08; 6(257):ra2.
Score: 0.028
-
Modeling precision treatment of breast cancer. Genome Biol. 2013; 14(10):R110.
Score: 0.028
-
An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci. 2012 Sep 24; 10(1):56.
Score: 0.027
-
Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCa invasive signaling axis. Sci Signal. 2012 Sep 11; 5(241):ra66.
Score: 0.027
-
Bayesian inference of signaling network topology in a cancer cell line. Bioinformatics. 2012 Nov 01; 28(21):2804-10.
Score: 0.027
-
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res. 2012 Nov 01; 18(21):5911-23.
Score: 0.027
-
Network inference using steady-state data and Goldbeter-Koshland kinetics. [corrected]. Bioinformatics. 2012 Sep 15; 28(18):2342-8.
Score: 0.027
-
Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. PLoS One. 2012; 7(6):e39400.
Score: 0.027
-
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012; 8(3):e1002538.
Score: 0.026
-
A time-series DDP for functional proteomics profiles. Biometrics. 2012 Sep; 68(3):859-68.
Score: 0.026
-
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J. 2012 Apr; 26(4):1582-92.
Score: 0.026
-
Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med. 2012 Jan; 4(1):52-67.
Score: 0.026
-
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell. 2011 May 20; 42(4):524-35.
Score: 0.025
-
PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One. 2010 Jul 23; 5(7):e11729.
Score: 0.023
-
Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 2010 Sep 01; 70(17):6704-14.
Score: 0.023
-
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res. 2010 May 15; 16(10):2852-60.
Score: 0.023
-
Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5012-7.
Score: 0.023
-
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther. 2010 Feb; 9(2):257-67.
Score: 0.022
-
Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochem Pharmacol. 2010 Mar 15; 79(6):842-52.
Score: 0.022
-
miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010 Feb; 17(2):246-54.
Score: 0.022
-
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32.
Score: 0.022
-
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One. 2009; 4(5):e5583.
Score: 0.021
-
Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell. 2009 Apr 07; 15(4):304-14.
Score: 0.021
-
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008 Dec; 118(12):3917-29.
Score: 0.021
-
Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res. 2008 Apr 15; 68(8):2895-903.
Score: 0.020
-
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 01; 68(1):206-15.
Score: 0.019
-
Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. ChemMedChem. 2007 Dec; 2(12):1789-98.
Score: 0.019
-
A module of negative feedback regulators defines growth factor signaling. Nat Genet. 2007 Apr; 39(4):503-12.
Score: 0.018
-
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006 Oct; 5(10):2512-21.
Score: 0.018
-
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006 Apr 01; 66(7):3737-46.
Score: 0.017
-
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006 Mar; 9(3):225-38.
Score: 0.017
-
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006 Mar; 5(3):637-44.
Score: 0.017
-
Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther. 2005 Nov; 4(11):1681-8.
Score: 0.017
-
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005 Apr; 4(4):346-55.
Score: 0.016
-
Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem. 2005 Jan 21; 280(3):2092-104.
Score: 0.016
-
Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem. 2003 Jun 27; 278(26):23630-8.
Score: 0.014
-
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 2003 Apr; 17(4):575-88.
Score: 0.014
-
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene. 2002 Apr 04; 21(15):2357-64.
Score: 0.013
-
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002 Feb 15; 62(4):1087-92.
Score: 0.013
-
Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer. 2001 Jul 20; 85(2):303-11.
Score: 0.012
-
Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. Cancer Res. 2001 Jul 15; 61(14):5486-90.
Score: 0.012
-
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999 Jan; 21(1):99-102.
Score: 0.010
-
Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998 Dec 01; 58(23):5285-90.
Score: 0.010